The Policies reinforce Prati-Donaduzzi's image as an integral and trustworthy company
From a work carried out by Deloitte Consulting, Prati-Donaduzzi Pharmaceutical Industry - a 100% national company and the largest generic drug manufacturer in Brazil *, has strengthened its Governance policies in order to meet global market standards which increasingly value this issue.
The starting point was a reanalysis of the Code of Ethics and internal processes of the organization, as well as the survey of other important points of the various areas of the company always with the purpose of evaluating and mitigating risks of non-compliance, fraud, and always seeking the operation improvement by protecting the reputation of the company.
The Policies reinforce Prati-Donaduzzi's image as an integral and trustworthy company, which complies with the legal requirements related to the activities it carries out, but also follows the internationally recognized high quality standards and good practices.
According to the Chief Financial Officer of the Industry, Marcelo Safadi Alvares, there are numerous advantages of this strengthening. "We have started this work in order to bring greater robustness to the company. Thus, through a committee created internally, we will reinforce the corporate governance policy in the various sectors of the company, and we will allow the company to be in line with the usual requirements practiced by the market", he emphasizes.
A meeting involving Prati-Donaduzzi Directors and Managers was presented with the results and actions developed by the Consultancy. At the time, the participants were given the new edition of the Code of Ethics, reformulated and reissued in accordance with the most modern practices in corporate governance.
For Prati-Donaduzzi CEO, Eder Fernando Maffissoni, the implementation of Compliance reinforces the importance of daily integrity. "We are a young company, but it has grown rapidly in recent years. The implementation of Compliance allows all of us employees to perform activities in accordance with what is stated in our code of ethics and conduct", he says.
The next steps include presenting the results to all Industry managers as well as the responsibilities and commitment needed to ensure that all practices continue to meet the general Compliance guidelines.
Prati-Donaduzzi, the pharmaceutical industry specializing in the development and production of generic and similar drugs, is the first in the country to market fractional drugs. Based in Toledo, western Paraná, Prati-Donaduzzi has more than 4,500 employees and has one of the largest portfolios of generic drugs in Brazil. It produces, on average, 12 billion therapeutic doses per year.